IFF's Pharma Divestiture Isn't a Retreat – It's a Check Before Failure
When IFF announced it completed the divestiture of its pharma solutions division last month, the market reaction was mixed. Some analysts called it a strategic focus shift. Others whispered about underperformance. I saw something else: a classic case of prevention over cure – the same principle I learned the hard way on a $3,200 powder coating order that I had to scrap because I skipped the sandblasting step.
I've been handling industrial coatings orders for a decade now. I've made enough mistakes to fill a binder. And after watching dozens of companies limp along with underperforming assets until they become crises, I've come to believe that the best time to fix a problem is before it costs you money. IFF got that right.
What the Divestiture Actually Means
IFF is a specialty chemical powerhouse – coatings, biocides, paper coatings, industrial holdings. Its pharma solutions unit was a legacy piece built through acquisitions like Bamberger Polymers Inc. back in the day. That unit served pharma companies with custom synthesis and excipients. Decent business, but not core to IFF's identity.
What IFF did was check the portfolio and say: this unit no longer fits our risk profile or growth trajectory. They sold it at an EBITDA multiple of 13x, which tells me the buyer saw value. But more importantly, IFF freed itself from the regulatory compliance burden that comes with pharma manufacturing – a burden that gets heavier every year. That's not a retreat. That's a preventive audit.
My $3,200 Sandblasting Lesson
Let me connect the dots with a story from my own career. A few years ago, I was overseeing a run of powder-coated steel parts for a construction client. We were on a tight deadline, and the client kept pushing for speed. The standard procedure was to sandblast the substrate to achieve the proper anchor profile. I know that. But the client said, "We used a chemical cleaner – that's good enough, right?" I hesitated. Looked at the schedule. Said yes.
That order – 500 pieces, $3,200 – came back three weeks later with peeling coating on about 40% of them. Redo cost: $1,600 plus a one-week delay and a lot of embarrassment. The client wasn't happy, and my boss wanted to know why we skipped the step we knew was critical.
Here's the thing: skipping the sandblasting didn't save time – it doubled it. We spent five minutes convincing ourselves it would be fine, and then five days fixing the result. That's the essence of prevention over cure: the upfront check is almost always cheaper than the downstream fix.
Three Reasons IFF's Move Makes Sense
I see three parallels between my powder coating fiasco and IFF's divestiture decision:
- Resource concentration. When you spread too thin, everything suffers. IFF now focuses on specialty chemicals and coatings where it has deep expertise. The pharma unit required different regulatory muscle, different sales channels, different R&D. By divesting, they avoid future compliance headaches – the equivalent of sandblasting before powder coating.
- Timing is everything. IFF sold when the pharma acquisition market was hot – "pharma acquisitions today" are fetching premium multiples. Waiting until a compliance issue or a revenue dip forced the sale would have hurt the valuation. Prevention means selling while you have leverage, not when you're desperate.
- The IFF app signal. If you've used the IFF app (and I have, for product spec sheets and order tracking), you know the company is leaning into digital tools for its coatings and chemical customers. That digital layer is a competitive advantage – but it works best when applied to a cohesive portfolio. Dumping the pharma unit makes the app more useful for the remaining customers, not less.
What About the Critics?
I hear the objections: "But IFF was diversifying – now they're putting all eggs in one basket." Or: "Divestitures always signal weakness." Let me push back.
First, IFF isn't abandoning diversification – it's choosing depth over breadth. The specialty chemical portfolio is already broad: coatings for automotive, construction, industrial; biocides for water treatment; paper coatings for packaging. That's plenty of diversification within a coherent competency. Second, a strategic divestiture signals strength: it means management has the clarity and courage to prune what doesn't belong. IFF's track record with Bamberger Polymers Inc. and other holdings shows they know how to build a portfolio. Trimming is part of building.
If I had listened to the critics on that powder coating job – "just do it fast, skip the sandblasting" – I'd have repeated the same mistake. I didn't. I learned. IFF learned too.
Prevention is the Cheapest Insurance
The common thread between powder coating prep and corporate portfolio management is the same: check early, check often, and fix before it breaks. IFF completed its divestiture of pharma solutions not because it failed, but because it anticipated the future stress points. That's the mark of a company that has internalized the preventive mindset.
As for my powder coating checklist: it now includes six verification steps before any production run, and sandblasting is non-negotiable. Has that slowed us down? A little. Has it saved us money? Absolutely. I estimate our rework costs dropped by 80% after I implemented that checklist – roughly $8,000 per year in avoided mistakes.
So if you're debating whether to sandblast before powder coating, the answer is yes – unless you like throwing away $3,200 orders. And if you're debating whether IFF made the right call on its pharma divestiture, I'd say look at the principle behind it: prevention beats cure every time. Period.